is mounjaro a glp 1 med GLP-1 receptor agonists What Makes Mounjaro Different From

INTRODUCTION In patients with type 2 diabetes with overweight and no cardiovascular disease or moderate risk of cardiovascular disease, metformin is the recommended initial treatment (class IIa recommendation)

As our findings are based on good-quality studies that were all multinational double-blind randomized placebo-control trials and our meta-analysis was based on a mean follow-up of 3.45 years (minimum 1.5 year maximum 5.4 years), the confounding and attrition bias are controlled, so the risk of unreliable results is diminished

Theres no outrunning the GLP-1 wave Given the ongoing wave of media coverage, a class of drugs known as GLP-1 agonists is becoming increasingly well-known

Cardiometabolic Benefits : Lower blood pressure and inflammation markers in certain contexts

Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes